pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.)(pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.))

概要

基本信息

药物类型

通用抗原疫苗、DNA疫苗、治疗性疫苗

别名-

靶点

HPV E7

作用方式

调节剂

作用机制

E7调节剂(人乳头瘤病毒E7蛋白调节剂)

治疗领域

肿瘤

在研适应症-

非在研适应症

头颈部肿瘤

原研机构

Ichor Medical Systems, Inc.

在研机构-

非在研机构

Ichor Medical Systems, Inc.

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.) 相关的临床试验

NCT01493154

/ Terminated临床1期IIT

A Phase I Clinical Trial Assessing the Safety and Feasibility of Administration of pNGVL4a-CRT/E7(Detox) DNA Vaccine Using the Intramuscular TriGridTM Delivery System in Combination With Cyclophosphamide in HPV-16 Associated Head and Neck Cancer Patients

This study will test the safety of an HPV DNA vaccine after it is injected into your muscle using an electroporation device (TriGridTM Delivery System made by Ichor Medical Systems), and will test the ability of the vaccine to help your body's immune system to recognize HPV-infected and associated cancer cells. In addition to giving the vaccine using an electroporation device, we are giving the vaccine in combination with an immunomodulatory agent to further enhance immune responses against HPV-infected and associated cancer cells.

开始日期2012-04-01

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+2]

NCT00988559

/ Completed临床1期IIT

A Pilot Study of pnGVL4a-CRT/E7 (Detox) for the Treatment of Patients With HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)

This study will test the efficacy and safety of different routes of administration of a DNA vaccine in patients with HPV16+ CIN2/3. Subjects will be enrolled in one of six treatment groups. Subjects enrolled in the first two groups will receive vaccination intradermally with a needle-free delivery device. Subjects enrolled in groups 3 and 4 will receive vaccination intramuscularly. Subjects enrolled in groups 5 and 6 will receive vaccine intralesionally.

开始日期2009-09-01

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+2]

100 项与 pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.) 相关的专利（医药）

登录后查看更多信息

100 项与 pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头颈部肿瘤	临床1期	美国	Ichor Medical Systems, Inc.	2012-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00988559 (CTgov)	临床1期	宫颈上皮内瘤样病变	132	Gene gun vaccine+DNA vaccination (PMED Delivery - Groups 1 and 2)	鑰繭艱齋繭製顧廠襯繭 = 繭窪簾鑰襯顧鹽壓獵廠壓醖願廠製蓋蓋築網衊 (糧觸遞築餘觸廠艱構遞, 鑰製淵範艱夢選衊壓鏇 ~ 繭簾鹽餘憲鹹繭糧鹽鹽) 更多	-	2018-07-09
				therapeutic resection of the lesion+intramuscular vaccination+DNA vaccination (IM Injections - Groups 5 and 6)	鑰繭艱齋繭製顧廠襯繭 = 鹽顧構憲憲襯醖築窪鑰壓醖願廠製蓋蓋築網衊 (糧觸遞築餘觸廠艱構遞, 顧齋鑰觸醖蓋顧遞鹽醖 ~ 襯鏇觸鑰鑰範遞簾範壓) 更多